Comparative Pharmacology
Head-to-head clinical analysis: FELBATOL versus TIAGABINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FELBATOL versus TIAGABINE HYDROCHLORIDE.
FELBATOL vs TIAGABINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
Tiagabine inhibits GABA reuptake into presynaptic neurons and glial cells by binding to the GAT-1 GABA transporter, thereby increasing synaptic GABA concentrations and enhancing inhibitory neurotransmission.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
Initial: 4 mg orally once daily; titrate by 4-8 mg/day at weekly intervals. Maintenance: 32-56 mg/day divided 2-4 times daily. Maximum dose: 56 mg/day.
None Documented
None Documented
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
Terminal half-life of 5–8 hours in healthy adults; prolonged to 12–16 hours in hepatic impairment. Reduces with enzyme-inducing co-medications.
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Primarily hepatic metabolism via CYP3A4, with <2% excreted unchanged in urine. 63% of dose excreted in feces, 25% in urine as metabolites.
Category C
Category A/B
Anticonvulsant
Anticonvulsant